Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the pancreas (WHO VI or VII) * Male or female participants who are at least 18 years of age on the day of signing informed consent * Primary resectable or borderline resectable disease (DPCG criteria) * ECOG performance status 0 or 1 * Ability to undergo surgery, radiotherapy, chemotherapy and immunotherapy * Leucocytes (WBC) ≥ 3.0 X 10\*9/l, Platelets ≥ 100X 10\*9 /l, Hemoglobin ≥ 6 mmol/l, Renal function: E-GFR \> 50 ml/min, Bilirubin \< 50 µmol/l or planned for biliary drainage * A male participant must agree to use a contraception as detailed in Appendix 6 of this protocol during the treatment period and for at least 18 weeks after the last dose of study treatment and refrain from donating sperm during this period. * A female participant is eligible to participate if she is not pregnant (see Appendix 6), not breastfeeding, and at least one of the following conditions applies: Not a: woman of childbearing potential (WOCBP) OR WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 18 weeks after the last dose of study treatment Written informed consent Exclusion criteria * Metastatic or locally advanced (i.e. unresectable) pancreatic cancer. * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137). * Has received pri…